Postbiotic composition for regulating development of intestinal cells and application thereof

The epibiotic composition was prepared by fermenting the metabolites of Lactobacillus mucinous, C. rhamnosus and Akmangii mucophila, and the epibiotic composition was prepared for the culture of mouse small intestine organoids, and the regulation of intestinal cell development in the prior art was solved. The problems of insufficient and long evaluation cycle have achieved significant intestinal cell promotion effects and rapid evaluation.

CN118931758APending Publication Date: 2024-11-12XIAMEN TREATGUT BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410770319.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, there are fewer posterior organs that have the efficacy of well regulate intestinal cell development, and the traditional intestinal efficacy evaluation methods have a long period and high cost, making it difficult to accurately reflect the true mechanism of posterior organs in the intestine.

Method used

Using the metabolites of Lactobacillus mucinous fermentation, C. rhamnosus TG017, C. rhamnosus TG021 and Akmangio mucophilin, the supernatant was collected and mixed by centrifugation through monocytogenes to prepare a posterior biogenic composition and pass through the mouse small intestine. Organoid culture method simulates the intestinal environment and evaluates its effectiveness in regulating intestinal cell development.

Benefits of technology

It significantly improves the expansion fold and budding rate of small intestinal organs, promotes the proliferation and differentiation of small intestinal organoids, shortens the evaluation cycle of posterior biogenesis regulation intestinal efficacy, and improves the accuracy and reliability of evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931758A_ABST
    Figure CN118931758A_ABST
Patent Text Reader

Abstract

The invention provides a metabolite composition for regulating intestinal cell development and a preparation method of the metabolite composition. The metabolite composition comprises a metabolite of lactobacillus mucus TG017, a metabolite of lactobacillus rhamnosus TG021 and a metabolite of Ackermann mucilaginosus. The preservation number of the lactobacillus mucus fermentation TG017 is CCTCC (China Center for Type Culture Collection) NO: M2023513, and the preservation number of the lactobacillus rhamnosus TG021 is CCTCC NO: M 2023486; the standard number of the ackermann muciniphile is GDMCC (China General Microbiological Culture Collection Center) 1.1346. The metagen composition can significantly improve the amplification multiple and budding rate of small intestine organs, and promote proliferation and differentiation of small intestine organs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a postbiotic composition for regulating intestinal cell development and application thereof, belonging to the technical field of postbiotic compositions. Background Art

[0002] Probiotics are mainly found in the human intestines, and play a beneficial role in the host by maintaining the balance of intestinal microorganisms. In recent years, studies have shown that probiotics can enhance immunity and maintain health. Probiotics are key members of the intestinal flora and affect intestinal health. In daily life, commercial probiotic-related products are gradually increasing. Understanding the efficacy of probiotics can be transformed into better health products. As the scope and function of human research on probiotics deepen, studies have shown that not only live bacteria can play a probiotic function, but some "non-live bacteria" components also show obvious probiotic effects, including probiotic metabolites, which contain enzymes, polypeptides, short-chain fatty acids, polysaccharides (such as extracellular polysaccharides) and other active substances. Postbiotics are a general term for the components of probiotic metabolites after probiotics are processed, including bacteria and metabolites. Studies have shown that probiotic metabolites have similar effects to probiotics, and have higher gastric acid tolerance and are easier to preserve than probiotics. However, there are few postbiotics in the prior art that have good effects on regulating intestinal cell development. Summary of the invention

[0003] The present invention provides a postbiotic composition for regulating intestinal cell development and application thereof, which can effectively solve the above problems.

[0004] The present invention is achieved in that:

[0005] A postbiotic composition for regulating intestinal cell development comprises metabolites of fermented Lactobacillus muciniphila TG017, metabolites of Lactobacillus rhamnosus TG021 and metabolites of Akkermansia muciniphila; the preservation number of the fermented Lactobacillus muciniphila TG017 is CCTCC NO: M 2023513, the preservation number of the Lactobacillus rhamnosus TG021 is CCTCC NO: M2023486; the standard number of the Akkermansia muciniphila is GDMCC1.1346.

[0006] In some embodiments, the sequence of the 16SrDNA of the fermentative Lactobacillus mucilaginosus TG017 is shown as SEQ ID NO:3; the sequence of the 16SrDNA of the Lactobacillus rhamnosus TG021 is shown as SEQ ID NO:2.

[0007] In some embodiments, the usage ratio of the metabolites of the fermented Lactobacillus muciniphila TG017, the metabolites of the Lactobacillus rhamnosus TG021, and the metabolites of Akkermansia muciniphila is 1:0.5-3.5:0.5-3.5.

[0008] A method for preparing the above-mentioned postbiotic composition for regulating intestinal cell development comprises culturing and fermenting Lactobacillus mucilaginosus TG017, Lactobacillus rhamnosus TG021 and Akkermansia muciniphila respectively, collecting metabolites, and mixing the metabolites.

[0009] In some embodiments, the culture is carried out anaerobic culture at 37° C. for 22-26 hours, and the culture medium is BHIS.

[0010] A method for culturing mouse small intestinal organoids, comprising the following steps:

[0011] S1, after killing the mice, remove the small intestinal tissue segment of 8-10 cm, rinse the small intestinal contents with ice-cold PBS, cut into intestinal segments, cut them open along the longitudinal axis, scrape the small intestinal villi with a sterile coverslip, discard the villi, and place the remaining tissue in cold PBS for later use;

[0012] S2, adding EDTA solution for digestion, dissociation and collection of intestinal crypts;

[0013] S3, prepare a suspension of matrix gel and intestinal crypts, inoculate it in a preheated culture vessel, then place it in a cell culture incubator at 36.5-37.5°C for incubation and solidification, add mIO CM for culture; add the postbiotic composition for regulating intestinal cell development into the mIO CM.

[0014] In some embodiments, the mIO CM is prepared by adding 10 v / v% FBS, 1 v / v% 100×GlutaMax, 1 v / v% 1M HEPES buffer, 1 v / v% 0.5M NAC, 0.1 v / v% 1000×Pen / Strep, 2 v / v% 50×B27, 1 v / v% 100×N2, 500 ng / mL R-spondin1, 100 ng / mL Noggin and 50 ng / mL EGF to Advanced DMEM / F12.

[0015] In some embodiments, the postbiotic composition for regulating intestinal cell development is added in an amount of 0.5-1.5 v / v%.

[0016] A mouse small intestinal organoid system cultured using the above method.

[0017] A use of the mouse small intestinal organoid system described above to evaluate the efficacy of postbiotics in regulating intestinal development.

[0018] The beneficial effects of the present invention are:

[0019] The present invention obtains a postbiotic composition by a method of single-bacteria fermentation, centrifugal collection and remixing of the supernatant, which can significantly increase the expansion multiple and budding rate of small intestinal organs at the same time, promote the proliferation and differentiation of small intestinal organoids, and has a good effect on regulating intestinal cell development.

[0020] The present invention cultivates a mouse small intestinal organoid system, constructs an intestinal organoid-postbiotic co-culture platform, and shortens the evaluation cycle of the intestinal regulation efficacy of postbiotics. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 This is a schematic diagram of the plate phenotype of Lactobacillus rhamnosus TG013.

[0023] Figure 2 The morphology and efficacy evaluation of Lactobacillus rhamnosus TG021, wherein (A) is a schematic diagram of the plate phenotype of Lactobacillus rhamnosus TG021; (B) DPPH radical scavenging rate of postbiotics of Lactobacillus rhamnosus TG021; (C) degradation rate of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) in cells by postbiotics of Lactobacillus rhamnosus TG021.

[0024] Figure 3 This is an evaluation of the morphology and efficacy of fermented Lactobacillus mucinous TG017, where (A) is the plate phenotype of fermented Lactobacillus mucinous TG017; (B) is the degradation rate of low-density lipoprotein cholesterol (LDL-C) in cells by postbiotics of fermented Lactobacillus mucinous TG017.

[0025] Figure 4 Figure 3 The effects of Akkermansia muciniphila (AKK) postbiotics on small intestinal organoids. (A) is the microscopic observation of the effects of Akkermansia muciniphila (AKK) postbiotics on the morphology of small intestinal organoids, and the microscope magnification is 100; (B) is the Image J quantitative analysis of the effects of Akkermansia muciniphila (AKK) postbiotics on the size of the area of ​​small intestinal organoid formation. "****" indicates a significant difference compared with the blank group (P<0.0001).

[0026] Figure 5The effects of Lactobacillus rhamnosus TG013 postbiotics on small intestinal organoids, where (A) is the microscopic observation of the effects of Lactobacillus rhamnosus TG013 postbiotics on the morphology of small intestinal organoids, and the microscope magnification is 100; (B) is the Image J quantitative analysis of the effects of Lactobacillus rhamnosus TG013 postbiotics on the size of the area formed by small intestinal organoids.

[0027] Figure 6 Figure 3 Effects of fermented Lactobacillus muciniphila TG017 postbiotics on small intestinal organoids. (A) is a microscopic observation of the effect of fermented Lactobacillus muciniphila TG017 postbiotics on the morphology of small intestinal organoids, with a microscope magnification of 100; (B) is an Image J quantitative analysis of the effect of fermented Lactobacillus muciniphila TG017 postbiotics on the size of the area of ​​small intestinal organoid formation. "****" indicates a significant difference compared with the blank group (P<0.0001).

[0028] Figure 7 Figure 3 The effects of postbiotics from Lactobacillus rhamnosus TG021 on small intestinal organoids. (A) is a microscopic observation of the effects of postbiotics from Lactobacillus rhamnosus TG021 on the morphology of small intestinal organoids, with a microscope magnification of 100. (B) is a quantitative analysis by Image J of the effects of postbiotics from Lactobacillus rhamnosus TG021 on the size of the area of ​​small intestinal organoid formation. "****" indicates a significant difference compared with the blank group (P<0.0001).

[0029] Figure 8 Figure 3 shows the effects of the postbiotic composition on small intestinal organoids. (A) shows the microscopic observation of the effects of the postbiotic composition on the morphology of small intestinal organoids, with a microscope magnification of 100. (B) shows the quantitative analysis of the effects of the postbiotic composition on the size of the small intestinal organoids formed using Image J. "****" indicates a significant difference compared with the blank group (P<0.0001). DETAILED DESCRIPTION

[0030] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] The embodiment of the present invention provides a postbiotic composition for regulating intestinal cell development, including metabolites of fermented Lactobacillus mucilaginosus TG017, metabolites of Lactobacillus rhamnosus TG021, and metabolites of Akkermansia muciniphila (AKK); the accession number of the fermented Lactobacillus mucilaginosus TG017 is CCTCC NO: M2023513, the accession number of the Lactobacillus rhamnosus TG021 is CCTCC NO: M 2023486; the standard number of Akkermansia muciniphila is GDMCC1.1346 (purchased from Guangdong Provincial Microbiological Culture Collection Center: https: / / www.gdmcc.net / # / index). The metabolites of fermented Lactobacillus mucilaginosus TG017, the metabolites of Lactobacillus rhamnosus TG021, and the metabolites of Akkermansia muciniphila (AKK) are mixed together to play a synergistic role and promote intestinal cell development.

[0032] In some embodiments, the sequence of the 16SrDNA of the fermentative Lactobacillus mucilaginosus TG017 is shown as SEQ ID NO:3; the sequence of the 16SrDNA of the Lactobacillus rhamnosus TG021 is shown as SEQ ID NO:2.

[0033] In some embodiments, the ratio of the metabolites of the fermented Lactobacillus mucilaginosus TG017, the metabolites of the Lactobacillus rhamnosus TG021, and the metabolites of Akkermansia muciniphila is 1:0.5-3.5:0.5-3.5. Under this ratio, it has a good effect of promoting the development of intestinal cells.

[0034] The present invention proposes a unique postbiotic composition that is designed to regulate the development of intestinal cells. This innovative composition is a mixture of metabolites from three different strains, namely, the metabolites of Lactobacillus mucilaginosus TG017, the metabolites of Lactobacillus rhamnosus TG021, and the metabolites of Akkermansia muciniphila (AKK). These strains have been carefully selected and studied in depth to ensure that their metabolites can play the greatest synergistic role in the development of intestinal cells.

[0035] First, let’s take a closer look at the background information of these three strains. Lactobacillus mucis fermentans TG017 is a probiotic with specific metabolic characteristics, and its preservation number is CCTCC NO: M 2023513. This strain has a unique ability to survive and reproduce in the intestinal environment and can produce a series of metabolites that are beneficial to the development of intestinal cells. Similarly, Lactobacillus rhamnosus TG021 is also an important probiotic, and its preservation number is CCTCC NO: M 2023486. This strain performs well in regulating the balance of intestinal microecology with its unique metabolic pathways and products. Finally, Akkermansia muciniphila (AKK) is a special intestinal microorganism with a standard number of GDMCC1.1346, which can be purchased from the Guangdong Provincial Microbial Culture Collection Center. This strain has attracted much attention for its ability to adhere to the intestinal mucosa and its role in promoting intestinal health.

[0036] In the postbiotic composition of the present invention, the metabolites of fermented Lactobacillus mucilaginosus TG017, the metabolites of Lactobacillus rhamnosus TG021, and the metabolites of Akkermansia muciniphila (AKK) are carefully proportioned to maximize the synergistic effect. Experimental data show that when the dosage ratio of these three metabolites is controlled within the range of 1:0.5-3.5:0.5-3.5, the composition has the most significant effect on promoting intestinal cell development. The choice of this ratio has been verified by a large number of experiments, aiming to ensure that various metabolites can fully exert their efficacy in the intestinal environment while avoiding unnecessary side effects.

[0037] In addition, in order to further understand the specific mechanism of action of these metabolites, the present invention also provides 16SrDNA sequence information of fermented Lactobacillus mucilaginosus TG017 and Lactobacillus rhamnosus TG021. These sequence information not only helps to further reveal the genetic characteristics and metabolic pathways of these two strains, but also provides valuable resources for subsequent research and development.

[0038] A method for preparing the above-mentioned postbiotic composition for regulating intestinal cell development, respectively culturing and fermenting Lactobacillus mucilaginosus TG017, Lactobacillus rhamnosus TG021 and Akkermansia muciniphila and collecting metabolites, and mixing the metabolites. The embodiment of the present invention prepares the postbiotic composition by single-bacteria fermentation, centrifugation, collecting the supernatant and then mixing, avoiding the problem of cross contamination, and by adjusting the fermentation supernatant ratio, a postbiotic composition with the function of regulating intestinal cell development is obtained, which can be applied in the fields of food or medical and health care, and has good application prospects.

[0039] In some embodiments, the culture is carried out anaerobic culture at 37° C. for 22-26 hours, and the culture medium is BHIS.

[0040] When preparing this postbiotic composition with the function of regulating intestinal cell development, we selected Lactobacillus mucilaginosus TG017, Lactobacillus rhamnosus TG021 and Akkermansia muciniphila as fermentation strains. These strains have unique advantages in regulating intestinal microorganisms and can produce a variety of biologically active metabolites.

[0041] During the preparation process, we first cultured these three strains separately. The culture conditions were 37°C in an anaerobic environment, using BHIS medium for 22-26 hours. This culture condition ensures that the strains grow and metabolize in the best state, thereby producing rich metabolites. The rich metabolites form postbiotics that have the function of regulating intestinal cell development.

[0042] Next, we collected the fermentation supernatant of each strain, i.e., the metabolites, by centrifugation. Centrifugation can effectively remove bacterial cells and retain pure metabolites. Then, we mixed these metabolites to form a postbiotic composition with the function of regulating intestinal cell development.

[0043] It is worth noting that the preparation method avoids the problem of cross-contamination between different strains by fermenting with a single strain, collecting the supernatant by centrifugation and then mixing. This method not only ensures the purity of the postbiotic composition, but also makes the preparation process simpler and more efficient.

[0044] In addition, by adjusting the ratio of the fermentation supernatant of each strain, we can obtain a postbiotic composition with different biological activities. This method of adjusting the ratio allows us to develop postbiotic products with specific functions according to actual needs to meet the health needs of different groups of people.

[0045] This postbiotic composition with the function of regulating intestinal cell development can be widely used in the fields of food or medical and health care. In the field of food, it can be used as a functional food additive and added to foods such as yogurt and beverages to improve the nutritional value and health functions of the food. In the field of medical and health care, it can be used as an intestinal microbial regulator to improve the balance of intestinal microecology, relieve the symptoms of intestinal diseases, and improve the quality of life of patients.

[0046] The present invention provides a method for culturing mouse small intestinal organoids, comprising the following steps:

[0047] S1, after killing the mice, remove the small intestinal tissue segment of 8-10 cm, rinse the small intestinal contents with ice-cold PBS, cut into intestinal segments, cut them open along the longitudinal axis, scrape the small intestinal villi with a sterile coverslip, discard the villi, and place the remaining tissue in cold PBS for later use;

[0048] S2, adding EDTA solution for digestion, dissociation and collection of intestinal crypts;

[0049] S3, prepare a suspension of matrix gel and intestinal crypts, inoculate it in a preheated culture vessel, then place it in a cell culture incubator at 36.5-37.5°C for incubation and solidification, add mIO CM for culture; add the above-mentioned postbiotic composition for regulating intestinal cell development to the mIO CM.

[0050] The present invention provides a method for culturing mouse small intestinal organoids, which is intended to simulate the physiological environment of the mouse small intestine for in-depth research. The entire culturing process is delicate and complex, covering a series of steps from sampling to culturing, ensuring that the growth and development of small intestinal organoids reach the optimal state.

[0051] First, in step S1, we selected healthy mice as experimental subjects. Under the premise of strictly following the ethics of animal experiments, after the mice were killed, we quickly removed their small intestinal tissue segments, which were about 8-10 cm in length. In order to maintain the activity of the tissue, the entire operation process must be performed on ice. Next, we rinse the contents of the small intestine with pre-cooled PBS (phosphate buffered saline) to ensure that there is no residue. Then, the small intestine is cut into appropriate intestinal segments and cut along the longitudinal axis to fully expose its internal structure. After that, we use a sterile coverslip to gently scrape off the small intestinal villi, which do not play a key role in the subsequent organoid culture, so they can be discarded. Finally, we place the remaining tissue in cold PBS for later processing.

[0052] In step S2, we added EDTA (ethylenediaminetetraacetic acid) solution to the PBS containing the small intestinal tissue for digestion. EDTA solution can destroy the connection between cells and dissociate the intestinal crypts from the tissue. This step is crucial for collecting intestinal crypts because intestinal crypts are the main source of small intestinal organoids. We collected the dissociated intestinal crypts through gentle manipulation and prepared them for subsequent culture.

[0053] Next is step S3, where we prepare a suspension of matrix gel and intestinal crypts. Matrix gel can provide support and nutrition for small intestinal organoids to ensure their normal growth. We mixed the collected intestinal crypts with matrix gel to form a suspension. Then, we inoculated this suspension in a preheated culture vessel to provide a suitable growth environment. Next, we placed the culture vessel in a cell culture incubator at 37°C for a period of time to allow the matrix gel to solidify and form a stable support structure.

[0054] Finally, we added mIO CM to the culture vessel for culture. This culture medium contains various nutrients and growth factors required for the growth of small intestinal organoids, which can simulate the physiological environment of the mouse small intestine. At the same time, we added a combination of postbiotics that regulate the development of intestinal cells to the culture medium. These postbiotics can affect the differentiation and function of cells in small intestinal organoids, making them closer to real small intestinal tissue.

[0055] Postbiotic compositions are a group of active ingredients that can regulate the development of intestinal cells. They are usually derived from probiotics, prebiotics or other natural bioactive substances. These ingredients have multiple biological functions such as promoting intestinal cell proliferation, differentiation, migration and apoptosis, and have an important impact on the growth and development of small intestinal organoids.

[0056] In order to fully exert the biological functions of the postbiotic composition, the researchers first need to determine its optimal addition concentration and combination. Through a series of experimental explorations, they found that adding a specific proportion of postbiotic composition to mIOCM can significantly promote the growth and development of small intestinal organoids.

[0057] During the entire culture process, we also need to pay close attention to the growth of small intestinal organoids and make appropriate adjustments and optimizations as needed. Through the culture method of the present invention, we can obtain mouse small intestinal organoids with physiological functions and morphological structures, providing a powerful tool for in-depth research on the physiological and pathological processes of the small intestine.

[0058] In some embodiments, the mIO CM is prepared by adding 10 v / v% FBS, 1 v / v% 100×GlutaMax, 1 v / v% 1M HEPES buffer, 1 v / v% 0.5M NAC, 0.1 v / v% 1000×Pen / Strep, 2 v / v% 50×B27, 1 v / v% 100×N2, 500 ng / mL R-spondin1, 100 ng / mL Noggin and 50 ng / mL EGF to Advanced DMEM / F12.

[0059] In multiple scientific studies, the culture of intestinal organoids has become an important tool for exploring the physiological functions and disease mechanisms of the small intestine. In order to successfully culture intestinal organoids, a suitable culture medium is crucial. In some carefully designed embodiments, we have selected a complete culture medium that has been carefully formulated based on Advanced DMEM / F12 to meet the specific needs of the growth and development of intestinal organoids.

[0060] First, Advanced DMEM / F12 is used as a basal medium to provide the necessary nutrients and growth factors for small intestinal organoids. However, relying solely on the basal medium is far from enough, so we also added a series of auxiliary components to further promote the growth and differentiation of small intestinal organoids.

[0061] Among them, 10v / v% FBS (fetal bovine serum) was added to the culture medium. FBS contains rich growth factors, hormones and other nutrients that can support the proliferation and differentiation of small intestinal organoids. In addition, 1v / v% 100×GlutaMax also provides the culture medium with sufficient glutamine, which is one of the amino acids necessary for cell growth.

[0062] In addition to these basic nutrients, 1v / v% 1M HEPES buffer was added to the culture medium. HEPES is a highly efficient buffer that can maintain the acid-base balance of the culture medium, thereby ensuring that the small intestinal organoids grow in a stable environment. In addition, 1v / v% 0.5M NAC (N-acetylcysteine) also plays an antioxidant role, helping to protect the small intestinal organoids from damage by oxidative stress.

[0063] To prevent microbial contamination in the culture medium, 0.1 v / v% 1000× Pen / Strep (penicillin / streptomycin) was added to the culture medium. This antibiotic mixture can effectively inhibit bacterial growth and ensure that the small intestinal organoids grow in a sterile environment.

[0064] In addition, 2v / v% 50×B27 and 1v / v% 100×N2 were added to the culture medium. These ingredients provide a variety of vitamins and minerals that are essential for the growth and differentiation of small intestinal organoids.

[0065] It is worth mentioning that 500ng / mL of R-spondin1, 100ng / mL of Noggin and 50ng / mL of EGF were specially added to the culture medium. These growth factors play a key role in the culture of small intestinal organoids. R-spondin1 can promote the proliferation and differentiation of small intestinal stem cells, while Noggin can inhibit the activity of the bone morphogenetic protein (BMP) signaling pathway, thereby contributing to the formation and maintenance of small intestinal organoids. EGF can stimulate the proliferation and differentiation of small intestinal epithelial cells and promote the maturation of small intestinal organoids.

[0066] In summary, this complete culture medium provides the best environment for the growth and differentiation of small intestinal organoids by carefully blending various nutrients and growth factors. It not only supports the proliferation and differentiation of small intestinal organoids, but also helps to study the physiological functions and disease mechanisms of the small intestine. With the continuous advancement of science and technology, it is believed that this culture medium will play an increasingly important role in the study of small intestinal organoids.

[0067] In some embodiments, the postbiotic composition for regulating intestinal cell development is added in an amount of 0.5-1.5% (v / v).

[0068] In some specific implementation cases, we describe in detail the amount of postbiotic composition added to regulate intestinal cell development. To ensure its efficacy and safety, we have determined the optimal addition range to be 0.5-1.5 v / v% through repeated tests and verifications.

[0069] This ratio is the result of careful calculation and repeated practice. First, we need to consider the content of active ingredients in the postbiotic composition, which is a key factor in determining its effect on regulating intestinal cell development. Within the range of 0.5-1.5% (v / v), the content of active ingredients is neither too high to cause unnecessary side effects nor too low to affect its regulatory effect.

[0070] In addition, we also need to consider the particularity of the intestinal environment. The intestine is a complex ecosystem with a large number of microorganisms and cells. The addition of postbiotic compositions needs to interact with other microorganisms and cells in this environment to jointly maintain intestinal health. Therefore, the appropriate amount of addition needs to consider not only the postbiotic composition itself, but also its adaptability to the intestinal environment.

[0071] It is worth mentioning that when we determined this addition amount, we also referred to a large amount of literature and empirical research results. These studies have shown that within the range of 0.5-1.5v / v%, the postbiotic composition can effectively regulate the development of intestinal cells and promote intestinal health. At the same time, this addition amount will not have a negative impact on other microorganisms in the intestine, maintaining the balance of intestinal microecology.

[0072] The present invention provides a mouse small intestinal organoid system cultured by the above method. This system can be used as an intestinal organoid-postbiotic co-culture platform, shortening the evaluation cycle of the intestinal regulation effect of postbiotics.

[0073] An embodiment of the present invention provides an application of the above-mentioned mouse small intestinal organoid system in evaluating the efficacy of postbiotics in regulating the intestine.

[0074] The present invention provides a unique mouse small intestinal organoid system that not only has a high degree of biological similarity, but also can simulate the complex structure and function of small intestinal tissue. The core of this system is to effectively grow and differentiate mouse small intestinal organoids in vitro through a carefully designed culture method, thereby constructing an experimental platform that approximates the real intestinal environment.

[0075] A major advantage of this mouse small intestinal organoid system is that it can serve as an ideal platform for co-cultivation of intestinal organoids and postbiotics. As an emerging bioactive substance, postbiotics have a variety of potential functions, such as regulating the balance of intestinal microecology and improving intestinal health. However, traditional intestinal efficacy evaluation methods often have long cycles and high costs, and it is difficult to accurately reflect the true mechanism of action of postbiotics in the intestine. The mouse small intestinal organoid system provided by the present invention can greatly shorten the evaluation cycle of postbiotics in regulating intestinal efficacy and improve the accuracy and reliability of the evaluation.

[0076] When constructing this system, we used advanced tissue engineering technology to provide sufficient nutrients and growth factors for organoids by simulating the growth environment of small intestinal tissue. At the same time, we also introduced postbiotics to achieve co-culture of intestinal organoids and postbiotics. In this process, postbiotics can interact with cells in organoids, thereby simulating their biological effects in the real intestine.

[0077] This system can also be used to screen postbiotics with specific intestinal regulatory functions, providing strong support for the development of new intestinal health products.

[0078] It is worth mentioning that the mouse small intestinal organoid system provided by the embodiment of the present invention not only has a wide range of application prospects, but also has high repeatability and operability, which makes the system highly valuable in both scientific research and practical applications.

[0079] Example 1 Isolation, purification and identification of Lactobacillus rhamnosus TG013, Lactobacillus rhamnosus TG021 and Lactobacillus fermentans TG017

[0080] Both rhamnosus Lactobacillus TG021 and TG013 were screened from fecal samples of healthy children in China. They are Gram-positive, with milky white, opaque, irregularly round colonies, wrinkled surfaces and irregular edges. The optimal growth temperature is 42°C, the optimal pH is 6 and the anaerobic environment is optimal. Among them, rhamnosus Lactobacillus TG021 has the ability to lower cholesterol, lower triglycerides and has antioxidant properties, and fermented mucus Lactobacillus TG017 has the effect of lowering blood lipids and can significantly reduce cholesterol and triglycerides. Rhamnosus Lactobacillus is important in promoting intestinal immune development, preventing inflammation-induced damage and stimulating intestinal barrier function.

[0081] The Lactobacillus rhamnosus TG013 was prepared from feces of healthy children in Xiamen, Fujian Province. The sample was inoculated into a mupirocin lithium salt modified MRS medium with a pH of 6.8 as a dispersed phase for enrichment culture using a droplet microfluidics system. The enrichment culture solution was aspirated on the 6th day and gradiently diluted with sterile saline to coat (mupirocin lithium salt modified MRS) agar plates (modified MRS medium formula: soy peptone 10.0 g / L; anhydrous glucose 10.0 g / L; phosphorus Dipotassium hydrogen sulfate 0.4g / L; yeast extract powder 5g / L; L-cysteine ​​salt 1g / L; magnesium sulfate 0.02g / L; diammonium hydrogen citrate 0.5g / L; the final pH is 6.8±0.2, sterilized at 121℃ for 20min, and when it drops to 50℃, add 50μg / mL mupirocin lithium salt and 60μg / mL neomycin sulfate to the culture medium at a final concentration), culture in an anaerobic incubator at 37℃ for 24h, pick a single colony and perform 3 rounds of streak purification on a modified MRS agar plate. The purified single colony was inoculated into a modified MRS liquid culture medium, cultured at 37℃, 200rpm shaking for 24-48h, and the genomic DNA was extracted using a bacterial genomic DNA rapid extraction kit for identification. The plate morphology of this strain is as follows Figure 1 As shown, the colonies were milky white, opaque, irregularly round, with wrinkled surfaces and irregular edges.

[0082] The Lactobacillus rhamnosus TG013 is deposited in the China Center for Type Culture Collection with the deposit number [CCTCC NO:M 2023036] and the deposit date [January 5, 2023]. Its 16SrDNA sequence is:

[0083] GAACGAGTTCTGATTATTGAAAGGTGCTTGCATCTTGATTTAATTTTGAAC

[0084] GAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGG

[0085] GATAACATTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATG

[0086] GTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGG

[0087] CGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCAATGATACGTAG

[0088] CCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAA

[0089] CTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTG

[0090] ATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCT

[0091] GTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTA

[0092] TCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACG

[0093] TAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCG

[0094] GTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGTGCATC

[0095] GGAAACTGGAAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGT

[0096] AGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGC

[0097] TGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAG

[0098] GATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGG

[0099] AGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTG

[0100] GGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGC

[0101] ACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTAC

[0102] CAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGG

[0103] GCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGT

[0104] TGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTT

[0105] AGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGG

[0106] GATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTAC

[0107] AATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTA

[0108] AAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCG

[0109] GAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGG

[0110] The rhamnosus Lactobacillus casei TG021 described in CCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTAGGGAGCGAGCCGTCTAA (SEQ ID NO: 1) was prepared by using feces of healthy children from Xiamen, Fujian as a sample, and the sample was inoculated into a mupirocin lithium salt-modified MRS medium with a pH of 6.8 for enrichment culture. On the 6th day, the enrichment culture fluid was aspirated and gradiently diluted with sterile physiological saline to coat (mupirocin lithium salt-modified MRS) agar plates (modified MRS medium formula: soy peptone 10.0 g / L; anhydrous glucose 10.0 g / L; dipotassium hydrogen phosphate 0.4g / L; yeast extract powder 5g / L; L-cysteine ​​salt 1g / L; magnesium sulfate 0.02g / L; diammonium hydrogen citrate 0.5g / L; final pH 6.8±0.2, sterilize at 121℃ for 20min, add 50μg / mL mupirocin lithium salt and 60μg / mL neomycin sulfate to the culture medium when it drops to 50℃), culture in an anaerobic incubator at 37℃ for 24h, pick a single colony and perform 3 rounds of streak purification on a modified MRS agar plate. Inoculate the purified single colony into a modified MRS liquid culture medium, culture at 37℃, 200rpm shaking for 24-48h, and use a bacterial genomic DNA rapid extraction kit to extract genomic DNA for identification. The plate morphology and function of this strain are shown in the following figure. Figure 2 As shown, the colonies are milky white, opaque, irregularly round, with wrinkled surfaces and irregular edges, and have the ability to lower cholesterol, lower triglycerides and have antioxidant properties.

[0111]

[0112] Fermented Lactobacillus mucus TG017 was screened from domestic healthy human fecal samples. The colonies are milky white, opaque, rounded, smooth and neatly edged. The optimal growth temperature is 37°C, the optimal pH is 6 and the anaerobic environment is suitable. It also has the ability to lower cholesterol. Fermented Lactobacillus can reduce the damage of harmful substances and bacteria to the intestinal mucosa and help improve intestinal health.

[0113] The fermented mucus Lactobacillus TG017 uses healthy human feces from Xiamen, Fujian as a sample, and the sample is inoculated into a human intestinal flora serum culture bottle for enrichment culture. The enrichment culture fluid is aspirated on days 1, 3, and 6, and the culture fluid is gradiently diluted with physiological saline and coated on an MRS agar plate (MRS culture medium formula: casein digest 10 g / L; beef extract powder 10 g / L; triammonium citrate 4 g / L; sodium acetate 5 g / L; magnesium sulfate heptahydrate 0.2 g / L; manganese sulfate tetrahydrate 0.05 g / L; potassium dihydrogen phosphate 2 g / L; glucose 20 g / L; Tween-80 1.08 g / L; final pH 5.7±0.2, sterilized at 115°C for 25 min), and after culturing in an anaerobic incubator at 37°C for 48 hours, a single colony is picked and streaked on an MRS agar plate for 3 rounds of purification. The purified single colony was inoculated into the modified MRS liquid medium, and cultured at 37°C, 200 rpm in a shaking incubator for 24-48 hours. The genomic DNA was extracted using a bacterial genomic DNA rapid extraction kit for identification. Figure 3 As shown, the colonies were milky white, opaque, irregularly round, with wrinkled surfaces and irregular edges, and had the ability to lower cholesterol.

[0114] The fermented mucus lactobacillus TG017 (Limosilactobacillus fermentum TG017) is deposited in the China Center for Type Culture Collection with the deposit number: CCTCC NO:M 2023513 and the deposit date is April 10, 2023. Its 16SrDNA sequence is: GTTACCCCACCGACTTTGGGTGTTACAAACTCTCATGGTGTGACGGGCGG TGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATT ACTAGCGATTCCGACTTCGTGCAGGCGAGTTGCAGCCTGCAGTCCGAACT GAGAACGGTTTTAAGAGATTTGCTTGCCCTCGCGAGTTCGCGACTCGTTG TACCGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGAT CTGACGTCGTCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCACTAGA GTGCCCAACTTAATGCTGGCAACTAGTAACAAGGGTTGCGCTCGTTGCGG GACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACC TGTCATTGCGTTCCCGAAGGAAACGCCCTATCTCTAGGGTTGGCGCAAGA TGTCAAGACCTGGTAAGGTTCTTCGCGTAGCTTCGAATTAAACCACATGCT CCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAACCTTGCGGT CGTACTCCCCAGGCGGAGTGCTTAATGCGTTAGCTCCGGCACTGAAGGGC GGAAACCCTCCAACACCTAGCACTCATCGTTTACGGCATGGACTACCAGG GTATCTAATCCTGTTCGCTACCCATGCTTTCGAGTCTCAGCGTCAGTTGCA GACCAGGTAGCCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTC CACCGCTACACATGGAGTTCCACTACCCTCTTCTGCACTCAAGTTATCCAG TTTCCGATGCACTTCTCCGGTTAAGCCGAAGGGTTTCACATCAGAATTAAA AAAACCGCCTGGCCTCTCTTTTCGCCCCAATAAATCCGGATAACGCTTGGCACCTACGTA(SEQ IDNO:3)。

[0115] Example 2 Preparation of Postbiotics

[0116] After activation on BHIS or BHIS+0.2% mucin solid medium, single colonies were picked and inoculated into liquid culture tubes. After culturing at 37°C in an anaerobic chamber for 24 h, the cell density was 1×10 6 CFU / mL, the culture medium is brain heart infusion broth BHIS, the formula of which is: 20g / L calf brain extract powder; 25g / L ox heart extract powder; 2.0g / L glucose; 10g / L peptone; 2.5g / L potassium dihydrogen phosphate; 5g / L yeast extract; 0.5g / L L-cysteine; 0.1mg / L resazurin mother solution; 2.5μg / L hemin mother solution; 0.05mg / L vitamin K1 mother solution; the final pH is 6.8-7.0. Take 2mL of bacterial solution into a centrifuge tube, centrifuge at 10000rpm, 4℃ for 10min, then take the supernatant, filter twice with 0.22μm microporous filter membrane, and then dilute with mL CM to 1% (v / v) of the original concentration for later use.

[0117] The Akkermansia muciniphila (AKK) standard number is GDMCC1.1346 (purchased from Guangdong Microbiological Culture Collection Center: https: / / www.gdmcc.net / # / index), which is a mucin-degrading bacterium found in human feces. It is an oval, strictly anaerobic, non-motile, Gram-negative bacterium that does not form endospores and is considered to be a "next generation probiotic". AKK is an intestinal commensal bacterium that adheres to the mucosal layer and plays an important role in improving host metabolic disorders and immune responses, and is closely related to the repair of the intestinal mucosal barrier.

[0118] The mIO CM is prepared by adding 10v / v% FBS, 1v / v% 100×GlutaMax, 1v / v% 1M HEPES buffer, 1v / v% 0.5M NAC, 0.1v / v% 1000×Pen / Strep, 2v / v% 50×B2, 1v / v% 100×N2, 500ng / mL R-spondin1, 100ng / mL Noggin and 50ng / mL EGF to Advanced DMEM / F12.

[0119] Example 3 Determination of the ability of postbiotics of Lactobacillus rhamnosus TG021 and Lactobacillus rhamnosus TG013 to scavenge DPPH free radicals

[0120] Preparation of DPPH sample solution: accurately weigh 20.0 mg of DPPH powder, place it in a 250 mL volumetric flask, dissolve it with anhydrous ethanol and dilute to the mark, mix well to obtain a 0.2 mmol / L DPPH solution, and store it at 4°C (use within 3.5 hours). Take 1 ml of bacterial supernatant, add 1 ml of 0.2 mmol / L DPPH, mix well, let it stand at room temperature for 30 minutes, use anhydrous ethanol as a blank control, and measure the absorbance change at 517 nm. The absorbance of each sample solution is measured at a wavelength of 517 nm as A1; the mixed solution of 1.0 mL of DPPH solution and 1.0 mL of anhydrous ethanol is used as a negative control to measure the absorbance A2; 1.0 mL of anhydrous ethanol solution is added to 1.0 mL of a mixed solution of different concentrations of each test solution as a blank control, and its absorbance A0 is measured. The clearance rate is calculated according to the formula (inhibition rate (%) = (1-(A1-A0) / A2) × 100%). DPPH is a very stable nitrogen-centered free radical. If the test substance can remove it, it means that the test substance has a significant antioxidant effect. Figure 2 (B) The scavenging rate of DPPH free radicals by postbiotics of Lactobacillus rhamnosus TG021 reached 28.38%, indicating that the postbiotics of this strain can efficiently scavenge free radicals.

[0121] Example 4 Verification of lipid-lowering function of postbiotics from fermented Lactobacillus mucilaginosus TG017

[0122] Construction of hyperlipidemia cell model.

[0123] (1) Preparation of modeling liquid.

[0124] Dissolve oleic acid in 0.1mmol / L NaOH in a 70℃ shaking water bath to prepare a 2.5mol / L storage solution. In a 55℃ shaking water bath, drop the above storage solution into a 20% BSA PBS solution to prepare a 250mmol / L working solution, filter and sterilize, and freeze at -20℃. Before use, place in a 55℃ water bath for 15 minutes and cool to room temperature, and dilute to 2.5mmol / L with DMEM culture medium (DMEM+10% FBS+double antibody).

[0125] (2) Cell modeling.

[0126] When the HepG2 cells grew to a density of about 80% to 90% in the culture flask, the cells were digested with trypsin and centrifuged (1000 rpm, 5 min). The cells were collected and plated on a 6-well plate. 2 mL of cell suspension was added to each well. The cell density was about 1×10 6Set up control group and experimental group, after the cells are completely attached, pour out the original culture medium, wash with PBS buffer, add DMEM culture medium (DMEM+10% FBS+double antibody) containing 2.5mmol / L oleic acid to the experimental group, and add normal DMEM culture medium (DMEM+10% FBS+double antibody) to the control group. Place the culture plate in an anaerobic incubator at 37℃ and cultivate for 24h. Wash the cells twice with PBS buffer, stain the cells with Sudan red III dye and then observe the staining results under a microscope. Determine the content of TG and LDL-C in the cells.

[0127] (3) Determination of lipid-lowering function of postbiotics from fermented Lactobacillus mucilaginosus TG017

[0128] Take 2mL of the cultured bacterial supernatant and BHIS culture medium and centrifuge (5000rpm, 4℃, 8min); take the supernatant, filter with a 0.22μm microporous filter membrane, and dilute the bacterial supernatant and BHIS culture medium three times with DMEM culture medium (DMEM+10% FBS+double antibody). Take DMEM culture medium, add 2mL of the treated supernatant, and use the BHIS group as the negative control group; culture in an anaerobic incubator at 37℃ for 24h. After the administration, discard the cell culture medium, wash the cells twice with PBS buffer, digest the cells with trypsin, centrifuge and discard the supernatant, wash the precipitate with PBS buffer, centrifuge and discard the supernatant, and add lysis solution to the cell precipitate. Centrifuge (12000rpm, 4℃, 3min), take the supernatant, and measure the content of TG and LDL-C in the cells. Results Figure 3 As shown in (B), after fermentation of Lactobacillus mucilaginosus TG017 in high-lipid cells for 24 hours, the degradation rate of low-density lipoprotein cholesterol (LDL-C) in the cells reached 20.03%.

[0129] Example 5 Collection of intestinal crypts from C57BL / 6 mice and culture of small intestinal organoids.

[0130] (1) Killing of mice: After killing the mice by cervical dislocation, the mice were immersed in 75% ethanol for 2-4 min and then placed in a sterile biosafety cabinet for dissection.

[0131] (2) Mouse dissection: The mouse was dissected and an 8-10 cm segment of small intestine tissue was removed. The contents of the small intestine were rinsed clean with ice-cold PBS, and the mesentery and fat outside the small intestine were removed. The intestine was cut into 2-3 cm segments, which were cut open along the longitudinal axis. The villi of the small intestine were scraped off with a sterile coverslip, and the villi were discarded. The remaining tissue was placed in cold PBS for later use;

[0132] (3) Intestinal crypt collection: The small intestine segment treated as above was cut into 2×2 mm small segments with scissors, placed in 10-15 mL PBS, and pipetted 5-10 times with a 10 mL gun. After pipetting, the cells were placed on ice for 0.5-1 min. After the tissue was completely settled, the supernatant was discarded, and 10-15 mL PBS was added. The washing was repeated five times. Finally, the PBS was discarded and 50 mL 2-5 mM EDTA solution was added. Incubate and digest in a 4°C refrigerator for 30-35 minutes; after the incubation, transfer to a 15mL centrifuge tube, let stand on ice for 0.5-1min, and after the tissue settles, remove the supernatant; slowly add 10mL of PBS along the tube wall, let stand on ice for 0.5-1min, and after the tissue settles, remove the supernatant, repeat the wash twice, remove the supernatant, add PBS again, and then use a 10mL pipette washed with an anti-adhesion agent to blow and aspirate 20 times, let stand on ice for 0.5-1min, after the tissue settles, pass the supernatant through a 70μM cell sieve, and the collected filtrate is the intestinal crypt. Continue to add PBS to the remaining tissue and repeat the wash five times. Centrifuge the collected intestinal crypt suspension at 4°C, 600g for 7-10min, discard the supernatant, add 1mL of PBS, gently shake to resuspend the intestinal crypt, transfer to a new centrifuge tube, centrifuge at 4°C, 100g for 1-2min, discard the supernatant, and repeat once;

[0133] (4) Small intestinal organoid culture: Add 300-500 μL of PBS depending on the amount of intestinal crypts, tap the tube wall to resuspend; inoculate 200-350 intestinal crypts per well. Pipette 50-100 μL of matrix gel (purchased from Bozhen Biotechnology Co., Ltd., main components: laminin, type IV collagen, enteric motilin / nitrogenase and heparin sulfate proteoglycan) and mix with the intestinal crypts, inoculate the mixture in a preheated 48-well plate, drop it in the center of the well, and spread it along the edge of the drop with a pipette tip to prevent the formation of a thick middle and thin edge phenomenon, which leads to uneven nutrient absorption of the organoids. Then place it in a 37°C cell culture incubator for incubation and solidification for 3-5 minutes. After the matrix gel is completely solidified, add 250-300 μL of preheated mIO CM containing postbiotics, and then continue to culture in a 37°C cell culture incubator. Replace fresh culture medium after 24 hours, and then replace fresh culture medium every 2-3 days.

[0134] Example 6 Effects of Akkermansia muciniphila (AKK) postbiotics on small intestinal organoid formation.

[0135] (1) Mice were killed, dissected, intestinal crypts were dissociated, and the collection and plating methods were the same as in Example 6. mIO CM without Akkermansia muciniphila (AKK) postbiotics was used as a blank control, and the culture medium was replaced with mIO CM containing 1% (v / v) Akkermansia muciniphila (AKK) postbiotics. Intestinal crypts were inoculated in 48-well plates, and mIO CM containing Akkermansia muciniphila (AKK) postbiotics was added for culture.

[0136] (2) Morphological determination: After 1 day of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 3 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 6 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; Image J software was used to analyze the characteristic parameters of all small intestinal organoids 1, 3, and 6 days after inoculation, including: the area size of all small intestinal organoids corresponding to 1, 3, and 6 days of culture, and the expansion multiples and budding rate of organoids corresponding to 6 days of culture and 1 day of culture.

[0137]

[0138] The experimental results showed that the organoid expansion factor of Akkermansia muciniphila (AKK) after 6 days of culture was 16.00±1.20 compared with 1 day of culture; the budding rate of organoids after 6 days of culture was 93.04±1.20%, and the area size changed as follows Figure 4 shown.

[0139] The results showed that co-culture of Akkermansia muciniphila (AKK) postbiotics for 6 days can promote the proliferation and differentiation of small intestinal organoids and can better promote the development of intestinal cells.

[0140] Example 7 Effect of Lactobacillus rhamnosus TG013 postbiotics on small intestinal organoid formation.

[0141] (1) Mice were killed, dissected, intestinal crypts were dissociated, and the collection and plating methods were the same as in Example 1. mIO CM without Lactobacillus rhamnosus TG013 postbiotics was used as a blank control, and the culture medium was replaced with mIO CM containing 1% (v / v) Lactobacillus rhamnosus TG013 postbiotics. Intestinal crypts were inoculated in 48-well plates and mIO CM containing Lactobacillus rhamnosus TG013 postbiotics was added for culture.

[0142] (2) Morphological determination: After 1 day of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 3 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 6 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; Image J software was used to analyze the characteristic parameters of all small intestinal organoids 1, 3, and 6 days after inoculation, including: the area size of all small intestinal organoids corresponding to 1, 3, and 6 days of culture, and the expansion multiples and budding rate of organoids corresponding to 6 days of culture and 1 day of culture.

[0143] The experimental results showed that the organoid expansion factor of Lactobacillus rhamnosus TG013 postbiotic culture for 6 days was 3.63±0.27 compared with that of 1 day; the budding rate of organoids after 6 days of culture was 70.96±1.55%, and the area size changed as follows Figure 5 shown.

[0144] The results showed that co-culture of Lactobacillus rhamnosus TG013 postbiotics for 6 days had no significant effect on the proliferation and differentiation of small intestinal organoids, and had no obvious effect on intestinal cell development.

[0145] Example 8 Effects of postbiotics from fermented Lactobacillus mucilaginosus TG017 on small intestinal organoid formation.

[0146] (1) Mice were killed, dissected, intestinal crypts were dissociated, and the collection and inoculation methods were the same as in Example 1. mIO CM without fermented Lactobacillus mucilaginosus TG017 postbiotics was used as a blank control, and the culture medium was replaced with mIO CM containing 1% (v / v) fermented Lactobacillus mucilaginosus TG017 postbiotics. Intestinal crypts were inoculated in 48-well plates and cultured with mIOCM containing fermented Lactobacillus mucilaginosus TG017 postbiotics.

[0147] (2) Morphological determination: After 1 day of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 3 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 6 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; Image J software was used to analyze the characteristic parameters of all small intestinal organoids 1, 3, and 6 days after inoculation, including: the area size of all small intestinal organoids corresponding to 1, 3, and 6 days of culture, and the expansion multiples and budding rate of organoids corresponding to 6 days of culture and 1 day of culture.

[0148] The experimental results are as follows: the organoid expansion factor after 6 days of fermentation of Lactobacillus mucilaginosus TG017 is 17.02±1.44 compared with 1 day of culture; the budding rate of organoids after 6 days of culture is 94.15±2.71%, and the area size changes are as follows Figure 6 shown.

[0149] Example 9 Effects of Lactobacillus rhamnosus TG021 postbiotics on small intestinal organoid formation.

[0150] (1) Mice were killed, dissected, intestinal crypts were dissociated, and the collection and plating methods were the same as in Example 1. mIO CM without Lactobacillus rhamnosus TG021 postbiotics was used as a blank control, and the culture medium was replaced with mIO CM containing 1% (v / v) Lactobacillus rhamnosus TG021 postbiotics. Intestinal crypts were inoculated in 48-well plates and cultured with mIOCM containing Lactobacillus rhamnosus TG021 postbiotics.

[0151] (2) Morphological determination: After 1 day of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 3 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; after 6 days of culture, photographs were taken under a 100x microscope to record the status of all organoids; Image J software was used to analyze the characteristic parameters of all small intestinal organoids 1, 3, and 6 days after inoculation, including: the area size of all small intestinal organoids corresponding to 1, 3, and 6 days of culture, and the expansion multiples and budding rate of organoids corresponding to 6 days of culture and 1 day of culture.

[0152] The experimental results showed that the organoid expansion factor of 6-day culture of Lactobacillus rhamnosus TG021 was 9.61±1.97 compared with 1-day culture; the budding rate of organoids after 6-day culture was 90.49±3.24%, and the area size changed as follows Figure 7 shown.

[0153] The results showed that co-cultivation of Lactobacillus rhamnosus TG021 postbiotics for 6 days can promote the proliferation and differentiation of small intestinal organoids and can better promote the development of intestinal cells.

[0154] Example 10 Effect of postbiotic composition on small intestinal organoid formation.

[0155] The mice were killed, dissected, and the intestinal crypts were dissociated, collected, and plated as in Example 1.

[0156] Mixtures containing Akkermansia muciniphila (AKK), Lactobacillus mucilaginosus TG017 and Lactobacillus rhamnosus TG021 were prepared in ratios of 1:1:1, 1:2:3, and 1:3:2, respectively. mIO CM without the mixture was used as a control, and mIO CM containing 1v / v% of the mixture was used as an experimental group. Intestinal crypts were inoculated in a 48-well plate, and mIO CM containing 1% (v / v) of the mixture was added for culture. The morphological and cell-level determination methods were the same as in Example 4. The organoid expansion multiples and organoid budding rates corresponding to 6 days of culture of each group of mixed solutions and 1 day of culture are shown in Table 1, and the area size changes and small intestinal organoid activity are shown in Table 1. Figure 8 shown.

[0157] Table 1 Characteristic parameters of small intestinal organoids: expansion multiple and budding rate

[0158]

[0159] The results showed that the mixed solution of AKK standard bacteria: fermented Lactobacillus mucilaginosus TG017: rhamnosus Lactobacillus casei TG021 with a ratio of 1:1:1, 1:2:3, and 1:3:2 could significantly increase the expansion multiples and budding rate of small intestinal organoids and promote the proliferation and differentiation of small intestinal organoids after 6 days of treatment. In short, compared with single bacterial postbiotics, the postbiotic combination has a stronger regulatory ability on intestinal development.

[0160] Example 11 Construction of intestinal organoid-postbiotic co-culture platform

[0161] The mice were killed, dissected, and the intestinal crypts were dissociated, collected, and plated as in Example 4.

[0162] A mixed solution containing a postbiotic composition of Akkermansia muciniphila (AKK), Lactobacillus muciniphila TG017 and Lactobacillus rhamnosus TG021 in a ratio of 1:3:2 was prepared respectively. The intestinal crypts were inoculated in a 48-well plate and mIO CM containing 1V / V% of the mixed solution was added for culture. An intestinal organoid-postbiotic co-culture platform was constructed to evaluate the efficacy of postbiotics in regulating intestinal cell development.

[0163] In summary, the present invention is a method for evaluating the efficacy of postbiotics based on the formation of small intestinal organoids, in which the intestinal crypts collected after small intestinal digestion of C57BL / 6 mice are co-cultured with postbiotics. The method can quickly screen the efficacy of postbiotics and provide strong support for the research and development and promotion of postbiotic products. At the same time, a new postbiotic composition is provided, which has a good effect of regulating intestinal cell development.

[0164] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A postbiotic composition for regulating intestinal cell development, It is characterized in that The invention comprises metabolites of fermented Lactobacillus mucilaginosus TG017, metabolites of Lactobacillus rhamnosus TG021 and metabolites of Akkermansia muciniphila; the preservation number of the fermented Lactobacillus mucilaginosus TG017 is CCTCC NO: M 2023513, the preservation number of the Lactobacillus rhamnosus TG021 is CCTCC NO: M 2023486; the standard number of the Akkermansia muciniphila is GDMCC1.1346.

2. The postbiotic composition for regulating intestinal cell development according to claim 1, It is characterized in that The sequence of 16SrDNA of the fermentative Lactobacillus mucilaginosus TG017 is shown in SEQ ID NO:3; the sequence of 16SrDNA of the Lactobacillus rhamnosus TG021 is shown in SEQ ID NO:

2.

3. The postbiotic composition for regulating intestinal cell development according to claim 1, It is characterized in that The usage ratio of the metabolites of the fermented Lactobacillus mucilaginosus TG017, the metabolites of the Lactobacillus rhamnosus TG021 and the metabolites of Akkermansia muciniphila is 1:0.5-3.5:0.5-3.

5.

4. A method for preparing the postbiotic composition for regulating intestinal cell development according to any one of claims 1 to 3, It is characterized in that Lactobacillus mucilaginosus TG017, Lactobacillus rhamnosus TG021 and Akkermansia muciniphila were cultured and fermented respectively, and their metabolites were collected and mixed.

5. The preparation method according to claim 4, It is characterized in that The culture conditions are as follows: anaerobic culture at 36.5-37.5° C. for 22-26 hours; the culture medium is brain heart infusion broth BHIS, and its formula is: 20 g / L calf brain extract powder; 25 g / L ox heart extract powder; 2.0 g / L glucose; 10 g / L peptone; 2.5 g / L dipotassium hydrogen phosphate; 5 g / L yeast extract; 0.5 g / L L-cysteine; 0.1 mg / L resazurin mother solution; 2.5 μg / L hemin mother solution; 0.05 mg / L vitamin K1 mother solution; and the final pH is 6.8-7.

0.

6. A method for culturing mouse small intestinal organoids, It is characterized in that The following steps are involved: S1, after killing the mice, remove the small intestinal tissue segment of 8-10 cm, rinse the small intestinal contents with ice-cold PBS, cut into intestinal segments, cut them open along the longitudinal axis, scrape the small intestinal villi with a sterile coverslip, discard the villi, and place the remaining tissue in cold PBS for later use; S2, adding EDTA solution for digestion, dissociation and collection of intestinal crypts; S3, prepare a suspension of matrix gel and intestinal crypts, inoculate it in a preheated culture vessel, then place it in a 37°C cell culture incubator for incubation and solidification, add small intestinal organoid complete culture medium (mIO CM) for culture; add the postbiotic composition for regulating intestinal cell development according to any one of claims 1 to 3 to the mIO CM.

7. The mouse small intestinal organoid culture method according to claim 6, It is characterized in that The mIO CM is prepared by adding 10v / v% FBS, 1v / v% 100×GlutaMax, 1v / v% 1M HEPES buffer, 1v / v% 0.5M NAC, 0.1v / v% 1000×Pen / Strep, 2v / v% 50×B27, 1v / v% 100×N2, 500ng / mL R-spondin1, 100ng / mL Noggin and 50ng / mL EGF to Advanced DMEM / F12.

8. The mouse small intestinal organoid culture method according to claim 6, It is characterized in that The postbiotic composition for regulating intestinal cell development is added in an amount of 0.5-1.5 v / v%.

9. A mouse small intestinal organoid system cultured by the method described in any one of claims 6 to 8.

10. An application of the mouse small intestinal organoid system described in claim 9 in evaluating the efficacy of postbiotics in regulating intestinal development.